Aurobindo Pharma gets approval for Alendronate Sodium Tabs
Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Alendronate Sodium Tablets USP 10mg, 35mg and 70mg. This is a Paragraph IV certification.
Alendronate Sodium Tablets are the generic equivalent of Merck & Co Inc’s Fosamax® Tablets USP 10mg, 35mg and 70mg, which are indicated for the treatment of Osteoporosis (bone disease). Annual sales of Alendronate Sodium Tablets USP 10mg, 35mg and 70mg in the US were approximately US$ 1,982 Million for the twelve months ending Dec 2007 according to Merck’s Financial Disclosures. Aurobindo is in the first line of generics and got the USFDA nod on the very first day post the expiry of the relevant patent and the product will be launched immediately in the US market. This has been one of fastest approvals received by the company, within 8 months of the date of filing
This is Aurobindo’s 73rd ANDA approval from the USFDA.
Tags: calls, daytrading, free calls, intraday, tips
Similar Posts:
Latest Query
- by Sam
Market Stats
Search Our Archives
Research Desk
- Stocks Trading above their 50 day moving average - DMA In Stock Research
- Download free Ebooks based on Technical Analysis In Personal Training
- TOP 100 Stocks with the Highest P/E as on July 14th, 2013 In Stock Research
- TOP 100 Stocks with the Lowest P/E as on July 14th, 2013 In Stock Research
- Charting Pathsala - Your guide to Techincals In Technical Analysis
